Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Code of Conduct [a]
CC transcript
|
|
EyePoint Pharmaceuticals, Inc. (EYPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/24/2023 |
4
| EW Healthcare Partners, L.P. (10% Owner) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Sold 46,778 shares
@ $14.6187, valued at
$683.8k
Sold 121,103 shares
@ $13.0543, valued at
$1.6M
|
|
| 08/22/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/22/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/04/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/27/2023 |
8-K
| Investor presentation |
| 07/12/2023 |
4
| Duker Jay S. (President and CEO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 50,000 restricted stock units
@ $0
Granted 100,000 options to buy
@ $9.11, valued at
$911k
|
|
| 07/12/2023 |
4
| Lurker Nancy (Executive Vice Chair) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 33,334 restricted stock units
@ $0
Granted 66,666 options to buy
@ $9.11, valued at
$607.3k
|
|
| 07/12/2023 |
4
| Zaderej Karen L. (Director) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Exercised 2,000 restricted stock units
@ $0 |
|
| 07/11/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/10/2023 |
8-K
| Quarterly results |
| 05/31/2023 |
4
| Liu Ye (Director) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Sold 1 shares
@ $6, valued at
$6 |
|
| 05/30/2023 |
4
| Pine Michael Craig (Chief Corp Dev.&Strat. Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 15,000 options to buy
@ $5.93, valued at
$89k
Granted 7,500 restricted stock units
@ $0 |
|
| 05/30/2023 |
4
| Elston George (CFO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 45,000 options to buy
@ $5.93, valued at
$266.9k
Granted 22,500 restricted stock units
@ $0 |
|
| 05/26/2023 |
144/A
| Form 144/A - Report of proposed sale of securities: [Amend] |
| 05/26/2023 |
144/A
| Form 144/A - Report of proposed sale of securities: [Amend] |
| 05/26/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/23/2023 |
8-K/A
| Financial Statements and Exhibits Interactive Data |
| 05/18/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...|
Docs:
|
"PRODUCT RIGHTS AGREEMENT between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc.",
"COMMERCIAL SUPPLY AGREEMENT This COMMERCIAL SUPPLY AGREEMENT is made as of May 17, 2023 , by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 480 Pleasant Street, Suite C-400, Watertown, MA 02472 , and Alimera Sciences, Inc., a Delaware corporation with its principal place of business at 6310 Town Square, Suite 400, Alpharetta, GA 30005 . Capitalized terms used, but not otherwise defined, in this Agreement have the meanings assigned to them in the Product Rights Agreement . RECITALS Whereas, EyePoint owns the rights to, and has commercialized in the United States, YUTIQ® 0.18 mg , which was approved by the U.S. Food and Drug Administration for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye...",
"EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties –$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt retired and expected cash runway extended into 2025 – EyePoint well-capitalized beyond key EYP-1901 Phase 2 DAVIO 2 and PAVIA clinical trial inflection points WATERTOWN, Mass., May 18, 2023 – EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that it has entered into a definitive agreement for the sale of YUTIQ® 0.18mg to Alimera Sciences, Inc. . YUTIQ is a treatment for chronic non-infectious uveitis affecting the posterior segment ..." |
|
| 05/15/2023 |
4
| Lurker Nancy (CEO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Gifted 21,250 options to buy
@ $36.3, valued at
$771.4k
Gifted 21,250 options to buy
@ $36.3, valued at
$771.4k
Gifted 65,868 options to buy
@ $26.5, valued at
$1.7M
Gifted 65,868 options to buy
@ $26.5, valued at
$1.7M
Gifted 36,000 options to buy
@ $20.4, valued at
$734.4k
Gifted 36,000 options to buy
@ $20.4, valued at
$734.4k
Gifted 8,000 options to buy
@ $17.7, valued at
$141.6k
Gifted 8,000 options to buy
@ $17.7, valued at
$141.6k
Gifted 120,206 options to buy
@ $13.13, valued at
$1.6M
Gifted 120,206 options to buy
@ $13.13, valued at
$1.6M
Gifted 59,220 options to buy
@ $12.9, valued at
$763.9k
|
|
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/03/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
SC 13G/A
| Cormorant Global Healthcare Master Fund, LP reports a 9.3% stake in EyePoint Pharmaceuticals, Inc. |
| 03/27/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/10/2023 |
8-K
| Other Events Interactive Data |
| 03/10/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|